311 related articles for article (PubMed ID: 17548127)
21. [Combination chemotherapy with carboplatin and weekly Paclitaxel in patients with advanced non-small cell lung cancer].
Hashizume T; Ogura T; Kozawa S; Yamaguchi N; Hayashi M; Nakamura M; Miyazawa N; Watanuki Y; Takahashi H
Gan To Kagaku Ryoho; 2006 Apr; 33(4):471-5. PubMed ID: 16612156
[TBL] [Abstract][Full Text] [Related]
22. Induction chemotherapy with carboplatin/paclitaxel followed by surgery or standard radiotherapy and concurrent daily low-dose cisplatin for locally advanced non-small cell lung cancer (NSCLC).
De Candis D; Stani SC; Bidoli P; Bedini VA; Potepan P; Navarria P; Aglione S; Bajetta E
Am J Clin Oncol; 2003 Jun; 26(3):265-9. PubMed ID: 12796598
[TBL] [Abstract][Full Text] [Related]
23. [Comparison of paclitaxel and carboplatin versus ifosfamide, etoposide, and carboplatin regimen for treatment of patients with advanced non-small cell lung cancer].
Li DX; Chen XB
Ai Zheng; 2002 Apr; 21(4):412-5. PubMed ID: 12452023
[TBL] [Abstract][Full Text] [Related]
24. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
[TBL] [Abstract][Full Text] [Related]
25. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
Charoentum C; Thongprasert S; Chewasakulyong B
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1603-7. PubMed ID: 17940374
[TBL] [Abstract][Full Text] [Related]
27. The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study.
Fabi A; Barduagni M; Ferraresi V; Cortesi E; Gamucci T; De Marinis F; Saltarelli R; Gabriele A; Pellicciotta M; Ceribelli A; De Marco S; Facciolo F; Cognetti F
J Exp Clin Cancer Res; 2004 Mar; 23(1):25-32. PubMed ID: 15149147
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.
Kosmidis P; Mylonakis N; Fountzilas G; Samantas E; Athanassiadis A; Pavlidis N; Skarlos D
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-30-S12-33. PubMed ID: 9331117
[TBL] [Abstract][Full Text] [Related]
29. Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a phase II study in advanced non-small cell lung cancer.
Roychowdhury DF; Desai P; Zhu YW
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-37-S12-40. PubMed ID: 9331119
[TBL] [Abstract][Full Text] [Related]
30. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.
Nakadate M; Yamazaki K; Konishi J; Kinoshita I; Sukoh N; Harada M; Akie K; Ogura S; Ishida T; Munakata M; Dosaka-Akita H; Isobe H; Nishimura M
Anticancer Res; 2006; 26(5B):3767-72. PubMed ID: 17094399
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
33. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer.
Mori K; Kamiyama Y; Kondo T; Kano Y; Kodama T
Cancer Chemother Pharmacol; 2006 Jul; 58(1):86-90. PubMed ID: 16447041
[TBL] [Abstract][Full Text] [Related]
34. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.
Neubauer M; Schwartz J; Caracandas J; Conkling P; Ilegbodu D; Tuttle T; Asmar L
J Clin Oncol; 2004 May; 22(10):1872-7. PubMed ID: 15143079
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
36. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): a preliminary study.
Ratanatharathorn V; Jirajarus M; Sirachainan E; Sirilerttrakul S; Euaree A; Supatchaipisit P
J Med Assoc Thai; 1998 Oct; 81(10):763-71. PubMed ID: 9803067
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of carboplatin, paclitaxel plus vinorelbine in non-small cell lung cancer patients.
Schmittel A; Siehl JM; Schulze M; Schulze K; Thiel E; Keilholz U
Anticancer Res; 2005; 25(2B):1333-6. PubMed ID: 15865087
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
Yanagitani N; Tsuchiya S; Kaira K; Sunaga N; Tsuchiya Y; Sato K; Watanabe S; Nomura S; Sakai S; Saito R; Mori M
Am J Clin Oncol; 2007 Oct; 30(5):487-91. PubMed ID: 17921708
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
